Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPM in Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
NCT06173349Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by University of California, Davis. Primary endpoint: Treatment related adverse events at 12 months. Started Nov 2023; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06173349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173349.